HC Wainwright Reiterates “Buy” Rating for Esperion Therapeutics (NASDAQ:ESPR)

Esperion Therapeutics (NASDAQ:ESPR)‘s stock had its “buy” rating reissued by HC Wainwright in a research report issued to clients and investors on Thursday,Benzinga reports. They currently have a $16.00 price target on the biopharmaceutical company’s stock.

Separately, StockNews.com downgraded Esperion Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 15th.

Esperion Therapeutics Trading Down 11.8 %

Shares of NASDAQ:ESPR opened at $2.25 on Thursday. The firm’s 50-day moving average is $2.39 and its 200 day moving average is $2.22. Esperion Therapeutics has a 12 month low of $1.58 and a 12 month high of $3.94. The company has a market capitalization of $443.34 million, a price-to-earnings ratio of -3.52 and a beta of 1.01.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. SG Americas Securities LLC grew its position in shares of Esperion Therapeutics by 45.3% during the 2nd quarter. SG Americas Securities LLC now owns 37,414 shares of the biopharmaceutical company’s stock worth $83,000 after buying an additional 11,658 shares in the last quarter. Bank of New York Mellon Corp increased its position in Esperion Therapeutics by 3,278.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 572,323 shares of the biopharmaceutical company’s stock valued at $1,271,000 after purchasing an additional 555,382 shares during the period. Summit Financial LLC raised its holdings in shares of Esperion Therapeutics by 26.4% in the 2nd quarter. Summit Financial LLC now owns 32,687 shares of the biopharmaceutical company’s stock valued at $73,000 after purchasing an additional 6,823 shares in the last quarter. Rhumbline Advisers lifted its position in shares of Esperion Therapeutics by 6,560.6% in the 2nd quarter. Rhumbline Advisers now owns 252,038 shares of the biopharmaceutical company’s stock worth $560,000 after purchasing an additional 248,254 shares during the period. Finally, Midland Wealth Advisors LLC bought a new position in shares of Esperion Therapeutics during the second quarter valued at approximately $133,000. Institutional investors own 47.39% of the company’s stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.